Management of herpes virus infections following transplantation. Report from the British Society for Antimicrobial Chemotherapy Working Party on Antiviral Therapy

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 6, 2000, Pages 729-748

  Pillay, Deenan ^a,b   Mutimer, David ^c   Singhal, Saket ^c   Turner, Andrew ^d   Ward, Katherine ^e   Wood, Martin ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d Newcastle Genetics Laboratory   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; CIDOFOVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; VALACICLOVIR;

CYTOMEGALOVIRUS; HERPES; HERPES VIRUS; HUMAN; ORGAN TRANSPLANTATION; PROPHYLAXIS; REVIEW;

EID: 0034129856     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.6.729     Document Type: Review

References (169)

1. Hirsch, M. S. (1994). Herpes group virus infections in the compromised host. In Clinical Approach to Infection in the Compromised Host, 3rd edn, (Robin, R. H. & Young, L. S., Eds), pp. 379-92. Plenum Medical Book Co., New York.
2. Reusser, P., Fisher, L. D., Buckner, C. D., Thomas, E. D. & Meyers, J. D. (1990). Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 75, 1888-94.
3. Meyers, J. D., Flournoy, N. & Thomas, E. D. (1982). Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years experience. Reviews in Infectious Diseases 4, 1119-32.
4. McDonald, G. B., Sharma, P., Hackman, R. C., Meyers, J. D. & Thomas, E. D. (1985). Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 88, 1111-7.
5. Spencer, G. D., Hackman R. C., McDonald G. B., Amos, D. E., Cunningham, B. A., Meyers, J. D. et al. (1986). A prospective study of unexplained nausea and vomiting after marrow transplantation. Transplantation 42, 602-7.
6. Wingard, J. R., Piantadosi, S., Burns, W. H., Zahurak, M. L., Santos, G. W. & Saral, R. (1990). Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Reviews in Infectious Diseases 12, Suppl. 7, S793-804.
7. Meyers, J. D., Ljungrnan, P. & Fisher, L. D. (1990). Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viraemia. Journal of Infectious Diseases 162, 373-80.
8. Meyers, J. D., Flournoy, N. & Thomas, E. D. (1986). Risk factors for cytomegalovirus infection after human marrow transplantation. Journal of Infectious Diseases 153, 478-88
9. Enright, H., Haake, R., Weisdorf, D., Ramsay, N., McGlave, P., Kersey, J. et al. (1993). Cytomegalovirus pneumonia after bone marrow transplantation risk factors and response to therapy. Transplantation 55, 1339-46.
10. Marks, D. I., Cullis, J. O., Ward, K. N., Lacey, S., Szydlo, R., Hughes, T. P. et al. (1993). Allogeneic bone marrow transplantation for chronic myeloid leukaemia using sibling and volunteer unrelated donors. A comparison of complications in the first two years. Annals of Internal Medicine 119, 207-14.
11. Li, C. R., Greenberg, P. D., Gilbert, M. J., Goodrich, J. M. & Riddell, S. R. (1994). Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83, 1971-9.
12. Ljungrnan, P., Engelhard, D., Link, H., Biron, P., Brandt, L., Brunet, S. et al. (1992). Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clinical Infectious Diseases 14, 831-5
13. Reed, E. C., Wolford, J. L., Kopecky, K. J., Lilleby, K. E., Dandliker, P. S., Todaro, J. L. et al. (1990). Ganciclovir for the treatment of cytomegalovirus gastro-enteritis in bone marrow transplant patients. A randomised placebo-controlled trial. Annals of Internal Medicine 112, 505-10
14. Bowden, R. A., Sayers, M., Flournoy, N., Newton, B., Banaji, M., Thomas, E. D. et al. (1986). Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. New England Journal of Medicine 314, 1006-10.
15. Miller, W. J., McCullough, J., Balfour, H. H., Jr, Haake, R. J., Ramsay, N. K., Goldman, A. et al. (1991). Prevention of cytomegalovirus infection following bone marrow transplantation: a randomised trial of blood product screening. Bone Marrow Transplantation 7, 227-34.
16. Bowden, R. A., Slichter, S. J., Sayers, M., Weisdorf, D., Cays, M., Schoch, G. et al. (1995), A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86, 3598-603.
17. Winston, D. J. & Gale, R. P. (1991). Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s. Bone Marrow Transplantation 8, 7-11.
18. Guglielmo, B. J., Wong-Beringer, A. & Linker, C. A. (1994). Immune globulin therapy in allogeneic bone marrow transplant: a critical review. Bone Marrow Transplantation 13, 499-510.
19. Meyers, J. D., Reed, E. C., Shepp, D. H., Thornquist, M., Dandliker, P. S., Vicary C. A. et al. (1988). Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. New England Journal of Medecine 318, 70-5.
20. Prentice, H. G., Gluckman, E., Powles, R. L., Ljungman, P., Milpied, N.J., Fernandez-Ranada, J. M. et al. (1994). Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 343, 749-53.
21. Goodrich, J. M., Boeckh, M. & Bowden, R. (1994). Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clinical Infectious Diseases 19, 287-98.
22. Ljungman, P., De Bock, R., Cordonnier, C., Einsele, H., Engelhard, D., Grundy, J. et al. (1993). Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT. Bone Marrow Transplantation 12, 399-403.
23. Boeckh, M., Gooley, T. A. & Bowden, R. A. (1998). Effect of high dose acyclovir on survival in allogeneic marrow transplant recipients who received ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia. Journal of Infectious Diseases 178, 1153-7.
24. Reusser, P., Dona, D., Cathomas, G., Tamm, M. & Gratwohl, A. (1997). Phase I/II trial of intravenous penciclovir followed by oral famciclovir for prevention of cytomegalovirus antigenemia and cytomegalovirus disease after allogeneic bone marrow or peripheral blood stem cell transplantation. In Program and Abstracts of the Thirty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997. Abstract H-77, American Society for Microbiology, Washington, DC.
25. Ljungman, P., Camara, R., Milpied, N., Volin, L., Reilly, L., Crisp, A. et al. (1999). Valaciclovir International Bone Marrow Transplant Study Group. Bone Marrow Transplantation 23, Suppl. 1, S65.
26. Atkinson, K., Downs, K., Golenia, M., Biggs, J., Marshall, G., Dodds, A. et al. (1991). Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection. British Journal of Haematology 79, 57-62.
27. Yau, J. C., Dimopoulos, M. A., Huan, S. D., Tarrand, J. J., Spencer, V., Spitzer, G. et al. (1991). Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. European Journal of Haematology 47, 371-6.
28. von Bueltzingsloewen, A., Bordigoni, P., Witz, F., Bene, M. C., Schmitt, C., Lacour, B. et al. (1993). Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 12, 197-202.
29. Winston, D. J., Ho, W. G., Bartoni, K., Du Mond, C., Ebeling, D. F., Buhles, W. C. et al. (1993). Ganciclovir prophylaxis of cylomegalovirus infection and disease in allogeneic bone marrow transplant recipients: results of a placebo-controlled, double blind trial. Annals of Internal Medicine 118, 179-84.
30. Goodrich, J. M., Bowden, R. A., Fisher, L., Keller, C., Schoch, G., Meyers, J. D. et al. (1993). Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Annals of Internal Medicine 118, 173-8.
31. Schmidt, G. M., Horak, D. A., Niland, J. C., Duncan, S. R., Forman, S. J., Zaia, J. A. et al. (1991). A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. New England Journal of Medicine 324, 1005-11.
32. Goodrich, J. M., Mori, M., Gleaves, C. A., Du Mond, C., Cays, M., Ebeling, D. F. et al. (1991). Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. New England Journal of Medicine 325, 1601-7.
33. Ward, K. N., Roberts, I. A. & Van Rhee, F. (1994). Ganciclovir and the prevention of CMV disease after allogeneic BMT: policy at the Hammersmith Hospital. Bone Marrow Transplantation 13, 230-1.
34. Bacigalupo, A., van Lint, M. T., Tedone, E., Moro, F., Sanna, M. A., Longren, M. et al. (1994). Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplantation 13, 753-8.
35. Atkinson, K., Arthur, C., Bradstock, K., Dale, B., Downs, K., Gibson, J. et al. (1995). Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplantation 16, 401-5.
36. Canpolat, C., Culbert, S., Gardner, M., Whimbey, E., Tarrand, J. & Chan, K. W. (1996). Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 17, 589-93.
37. Van der Bij, W., Torensma, R., van Son, W. J., Anema, J., Schirm, J., Tegzess, A. M. et al. (1988). Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. Journal of Medical Virology 25, 179-88.
38. Van der Bij, W., Schirm, J., Torensma, R., van Son, W. J., Tegzess, A. M. & The, T. H. (1988). Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. Journal of Clinical Microbiology 26, 2531-5
39. Jiwa, N. M., Van Gemert, G. W., Raap, A. K., Van de Rijke, F. M., Mulder, A., Lens, P. F. et al. (1989). Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viraemic transplant recipients by the polymerase chain reaction. Transplantation 48, 72-6.
40. Einsele, H., Ehninger, G., Hebart, H., Wittkowski, K. M., Schuler, U., Jahn, G. et al. (1995). Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 86, 2815-20.
41. Boeckh, M., Gooley, T. A., Myerson, D., Cunningham, T., Schoch, G. & Bowden, R. A. (1996). Cytomegalovirus pp65 anti-genaemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomised double-blind study. Blood 88, 4063-71.
42. Hirsch, M. S., Schooley, R. T., Cosimi, A. B., Russell, P. S., Delmonico, F. L., Tolkoff-Rubin, N. E. et al. (1983). Effects of interferon-alpha on cytomegalovirus reactivation syndromes in renal-transplant recipients. New England Journal of Medicine 308, 1489-93.
43. Lui, S. F., Ali, A. A., Grundy, J. E., Fernando, O. N., Griffiths, P. D. & Sweny, P. (1992). Double-blind, placebo-controlled trial of human lymphoblastoid interferon prophylaxis of cytomegalovirus infection in renal transplant recipients. Nephrology Dialysis Transplantation, 7 1230-7.
44. Cheeseman, S. H., Rubin, R. H., Stewart, J. A., Tolkoff-Rubin, N. E., Cosimi, A. B., Cantell, K. et al. (1979). Controlled clinical trial of prophylactic human-leucocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. New England Journal of Medicine 300, 1345-9.
45. Saliba, F., Arulnaden, J. L., Gugenheim, J., Serves, C., Samuel, D., Bismuth, A. et al. (1989). CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transplantation Proceedings 21, 2260-2.
46. Gofer, J. B., Morris, C. A., Sutker, W. L., Husberg, B. S., Goldstein, R. M., Gonwa, T. A. et al. (1991). A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplantation Proceedings 23, 1525-7.
47. Snydman, D. R., Werner, B. G., Dougherty, N. N., Griffith, J., Rubin, R. H., Dienstag, J. L. et al. (1993). Cytomegalovirus immune globulin for prophylaxis in liver transplantation. A randomized double-blind placebo-controlled trial. The Boston Centre for Liver Transplantation CMVIG Study Group. Annals of Internal Medicine 10, 984-91.
48. Greger, B., Vallbracht, A., Kurth, J., Schareck, W. D., Müller, G. H., Hopt, U. T. et al. (1986). The clinical value of CMV prophylaxis by CMV hyperimmune serum in kidney transplant patients. Transplantation Proceedings 18, 1387-9.
49. Fassbinder, W., Ernst, W., Hanke, P., Bechstein, P. B., Scheuerman, E. H., Schoeppe, W. et al. (1986). Cytomegalovirus infections after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transplantation Proceedings 18, 1393-6.
50. Snydman, D. R., Werner, B. G., Heinze-Lacey, B., Berardi, V. P.,Tilney, N. L, Kirkman, R. L. et al. (1987). Use of cytomegalovirus immune globulin to prevent Cytomegalovirus disease in renal-transplant recipients. New England Journal of Medicine 317, 1049-54.
51. Kasiske, B. L., Heim-Duthoy, K. L., Tortorice, K. L., Ney, A. L., Odland, M. D. & Rao, K. V. (1989). Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Archives of Internal Medicine 149, 2733-6.
52. Conti, D. J., Freed, B. M., Gruber, S. A. & Lempert, N. (1994). Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobin. Archives of Surgery 129, 443-7.
53. Saliba F., Eyraud, D., Samuel, D., David, M. F., Arulnaden, J. L., Dussaix, E. et al. (1993). Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transplantation Proceedings 25, 1444-5.
54. Green, M., Reyes, J., Nour, B., Beatty, D., Kaufman, M., Wilson, J. et al. (1994). Randomized trial of ganciclovir followed by high dose oral acyclovir vs. ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis. Transplantation Proceedings 26, 173-4.
55. Balfour, H. H., Jr, Chace, B. A., Stapleton, J. T., Simmons, R. L. & Fryds, D. S. (1989). A randomised placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. New England Journal of Medicine 320, 1381-7.
56. Dunn, D. L., Gillingham, K. J., Kramer, M. A., Schmidt, W. J., Erice, A., Balfour, H. H., Jr et al. (1994). A prospective randomised study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation. Transplantation 57, 876-84.
57. Kletzmayr, J., Kotzmann, H., Popow-Kraupp, T., Kovarik, J. & Klauser, R. (1996). Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in high-risk renal-transplant recipients. Journal of the American Society of Nephrology 7, 325-30.
58. Lowance, D., Neumayer, H. H., Legendre, C. M., Squifflet, J. P., Kovarik, J., Brennan, P. J. et al. (1999). Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. New England Journal of Medicine 340, 1462-70.
59. Cohen, A. T., O'Grady, J. G., Sutherland, S., Sallie, R., Tan, K. C. & Williams, R. (1993). Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. Journal of Medical Virology 40, 5-9.
60. Nakazato, P. Z., Burns, W., Moore, P., Garcia-Kennedy, R., Cox, K. & Esquivel, C. (1993). Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir. Transplantation Proceedings 25, 1935-7.
61. Martin, M., Manez, R., Linden, P., Estores, D., Torre-Cisneros, J., Kusne, S. et al. (1994). A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58, 779-85.
62. Winston, D. J., Wirin, D., Snaked, A. & Busuttil, R. W. (1995). Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 346, 69-74.
63. Badley, A. D., Seaberg, E. C., Porayko, M. K., Wiesner, R. H., Keating, M. R., Wilhelm, M. P. et al. (1997). Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 64, 66-73.
64. Gane, E., Saliba, F., Valdecasas, G. J., O'Grady, J., Pescovitz, M. D., Lyman, S. et al. (1997). Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. Lancet 350, 1729-33.
65. Flechner, S. M., Avery, R. K., Fisher, R., Mastroianni, B. A., Papajcik, D. A., O'Malley, K. J. et al. (1998). A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 66, 1682-8.
66. Rondeau, E., Bourgeon, B., Peraldi, M. N., Lang, P., Buisson, C., Schulte, K. M. et al. (1993). Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrology Dialysis Transplantations, 8, 858-62.
67. Leray, H., Mourad, G., Chong, M., Segondy, M. & Mion, C. (1995). Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients. Transplantation Proceedings 27, 2448.
68. Pouteil-Noble, C., Megas, F., Chapuis, F., Bosshard, S., Colin, C., Hadj-Aissa, A. et al. (1996). Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial. Transplantation Proceedings 28, 2811.
69. Stratta, R. J., Schaefer, M. S., Gushing, K. A., Markin, R. S., Reed, E. C., Langnas, A. N. et al. (1992). A randomised prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Archives of Surgery 127, 55-63.
70. Singh, N., Yu, V. L., Mieles, L., Wagener, M. M., Miner, R. C. & Gayowski, T. (1994). High-dose acyclovir compared with short course pre-emptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Annals of Internal Medicine 120, 375-81.
71. Metselaar, H. J., Rothbarth, P. H. & Brouwer, R. M., Wenting, G. J., Jeekel, J. & Weimar, W. (1989). Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 48, 264-6.
72. Conti, D. J., Freed, B. M., Singh, T. P., Gallichio, M., Gruber, S. A. & Lempert, N. (1995). Pre-emptive ganciclovir therapy in cytomegalovirus-seropositive renal transplant recipients. Archives of Surgery 130, 1217-21.
73. Hibberd, P. L., Tolkoff-Rubin, N. E., Conti, D., Stuart, F., Thistlethwaite, J. R., Neylan, J. F. et al. (1995). Pre-emptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial. Annals of Internal Medicine 123, 18-26.
74. Patel, R., Snydman, D. R., Rubin, R. G., Ho, M., Pescovitz, M., Martin, M. et al. (1996). Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 61, 1279-89.
75. Valantine, H. A. (1995). Prevention and treatment of cytomegalovirus disease in thoracic organ transplant: evidence for a beneficial effect of hyperimmune globulin. Transplantation Proceedings 27, Suppl. 1, 49-57.
76. Noble, S. & Faulds, D. (1998). Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 56, 115-46.
77. Merigan, T. C., Renlund, D. G., Keay, S., Bristow, M. R., Starnes, V., O'Connell, J. B. et al. (1992). A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. New England Journal of Medicine 326, 1182-6.
78. Macdonald, P. S., Keogh, A. M., Marshman, D., Richens, D., Harvison, A., Kaan, A. M. et al. (1995). A double-blind placebo-controlled trial of low dose ganciclovir to prevent cytomegalovirus disease after heart transplantation. Journal of Heart and Lung Transplantation 14, 32-8.
79. Aguado, J. M., Gomez-Sanchez, M. A., Lumbreras, C., Delgado, J., Lizasoain, M., Otero, J. R. et al. (1995). Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3. Antimicrobial Agents and Chemotherapy 39, 1643-5.
80. Duncan, S. R., Grgurich, W. F., Iacono, A. T., Burckart, G. J., Yousem, S. A., Paradis, I. L. et al. (1994). A comparison of ganciclovir and acyclovir to prevent cytomegalovirus infection after lung transplantation. American Journal of Respiratory Critical Care Medicine 150, 146-52.
81. Egan, J. J., Lomax, J., Barber, L., Lok, S. S., Martyszcuk, R., Yonan, N. et al. (1998). Pre-emptive treatment for the prevention of cytomegalovirus disease in heart and lung transplant recipients. Transplantation 65, 747-52.
82. Gerna, G., Zavattoni, M., Baldanti, F., Sarasini, A., Chezzi, L., Grossi, P. et al. (1998). Human cytomegalovirus (HCMV) leukodnaemia correlates more closely with clinical symptoms than anti-genemia and viremia in heart and heart-lung transplant recipients with primary HCMV infection. Transplantation 65, 1378-85.
83. Przpiorka, D., Ippoliti, C., Panina, A., Goodrich, J., Giralt, S., van Besien, K. et al. (1994). Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplantation 13, 461-4.
84. Canpolat, C., Culbert, S., Gardner, M., Whimbey, E., Tarrand, J. & Chan, K. W. (1996). Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients. Bone Marrow Transplantation 17, 589-93.
85. Stocchi, R., Szydlo, R., Craddock, C., Kanfer, E., Apperley, J. F., Goldman, J. M. et al. (1999). A comparison of prophylactic versus pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation. Bone Marrow Transplantation 23, 705-9.
86. Takenaka, K., Gondo, H., Tanimoto, K., Nagafuji, K., Fujisaki, T., Mizuno, S. et al. (1997). Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplantation 19, 241-8.
87. Atkinson, K., Arthur, C., Bradstock, K., Dale, B., Downs, K., Gibson, J. et al. (1995). Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group. Bone Marrow Transplantation 16, 401-5.
88. Salzberger, B., Bowden, R. A., Hackman, R. C., Davis, C. & Boeckh, M. (1997). Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 90, 2502-8.
89. Ippoliti, C., Morgan, A., Warkentin, D., van Besien, K., Mehra, R., Khouri, I. et al. (1997). Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplantation 20, 491-5.
90. Ljungman, P., Einsele, H., Lee, J. et al. (1999). A randomised study comparing ganciclovir and foscarnet for pre-emptive therapy of CMV infection in allogeneic SCT recipients. Bone Marrow Transplantation 23, Suppl. 1, Ex. 8.
91. Bacigalupo, A., Bregante, S., Tedone, E., Isaza, A., van Lint, M. T., Trespi, G. et al. (1996). Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation. Transplantation 62, 376-80.
92. Martin, J. C. & Hitchcock, M. J. (1991). Phosphonomethylether compounds as antiviral agents. Transplantation Proceedings 23, Suppl. 3, 156-8.
93. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E. & Greenberg, P. D. (1992). Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257, 238-41.
94. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. New England Journal of Medicine 333, 1038-44.
95. Gonczol, E., lanacone, J., Ho, W. Z., Starr, S., Meignier, B. & Plotkin, S. (1990). Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8, 130-6.
96. Walter, E. A. & Bowden, R. A. (1995). Infection in the bone marrow transplant recipient. Infectious Disease Clinics of North America 9, 823-47.
97. Meyers, J. D. & Atkinson, K. (1983). Infection in bone marrow transplantation. Clinics in Haematology 12, 791-811.
98. Shepp, D. H., Newton, B. A., Dandliker, P. S., Flournoy, N. & Meyers, J. D. (1985). Oral acyclovir therapy for mucocutaneous herpes simplex virus infections in immunocompromised marrow transplant recipients. Annals of Internal Medicine 102, 783-5.
99. Wade, J. C., Newton, B., McLaren, C., Flournoy, N., Keeney, R. E. & Meyers, J. D. (1982). Intravenous aciclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation: A double blind trial. Annals of Internal Medicine 96, 265-9.
100. Lazarus, H. M., Belanger, R., Candoni, A., Aoun, M., Jurewicz, R. & Marks, L. (1999). Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. Antimicrobial Agents and Chemotherapy 43, 1192-7.
101. Wade, J. C., McLaren, C. & Meyers, J. D. (1983). Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant recipients receiving multiple courses of treatment with acyclovir. Journal of Infectious Diseases 148, 1077-82.
102. Safrin, S., Crumpacker, C., Chatis, P., Davis, R., Hafner, R., Rush, J. et al. (1991). A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. New England Journal of Medicine 325, 551-5.
103. Balfour, H. H., Benson, C., Braun, J., Cassens, B., Erice, A., Friedman-Kien, A. et al. (1994). Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. Journal of AIDS 7, 254-60.
104. Snoeck, R., Andrei, G., Gerard, M., Silverman, A., Hedderman, A., Balzarini, J. et al. (1994). Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC). Clinical Infectious Diseases 18, 570-8.
105. LoPresti, A. E., Levine, J. F., Munk, G. B., Tai, C. Y. & Mendel, D. B. (1998). Successful treatment of an acyclovir-and foscarnet-resistant herpes simplex virus type 1 lesion with intravenous cidofovir. Clinical Infectious Diseases 26, 512-3.
106. Lalezari, J., Schacker, T., Feinberg, J., Gathe, J., Lee, S., Cheung, T. et al. (1997). A randomised, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovirunresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. Journal of Infectious Diseases 176, 892-8.
107. Saral, R., Burns, W. H., Laskin, O. L., Santos, G. W. & Lietman, P. S. (1981). Acyclovir prophylaxis of herpes simplex virus infections. New England Journal of Medicine 305, 63-7.
108. Lundgren, G., Wilczek, H., Lönnqvist, B., Lindholm, A., Wahren, B. & Ringdén, O. (1985). Acyclovir prophylaxis in bone marrow transplant recipients. Scandinavian Journal of Infectious Diseases Suppl. 47, 137-44.
109. Hann, I. M., Prentice, H. G., Blacklock, H. A., Ross, M. G., Brigden, D., Rosling, A. E. et al. (1983). Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. British Medical Journal Clinical Research Edition 287, 384-8.
110. Shepp, D. H., Dandliker, P. S., Flournoy, N. & Meyers, J. D. (1985). Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. Journal of Antimicrobial Chemotherapy 16, 389-95.
111. Wade, J. C., Newton, B., Flournoy, N. & Meyers, J. D. (1984). Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Annals of Internal Medicine 100, 823-8.
112. Gluckman, E., Lotsberg, J., Devergie, A., Zhao, X. M., Melo, R., Gomez-Morales, M. et al. (1983). Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet ii, 706-8.
113. Chou, S., Gallagher, J. G. & Merigan, T. C. (1981). Controlled clinical trial of intravenous acyclovir in heart transplant patients with mucocutaneous herpes simplex infections. Lancet i, 1392-4.
114. Heaton, A., Arze, R. S. & Ward, M. K. (1981). Acyclovir for life-threatening herpes simplex virus infection after renal transplantation. Lancet ii, 875.
115. Pettersson, E., Hovi, T., Ahonen, J., Fiddian, A. P., Salmela, K., Höckerstedt, K. et al. (1985). Prophylactic oral acyclovir after renal transplantation. Transplantation 39, 279-81.
116. Seale, L., Jones, C. J., Kathpalia, S., Jackson, G. G., Mozes, M., Maddux, M. S. et al. (1985). Prevention of herpes virus infections in renal allograft recipients by low-dose oral acyclovir, Journal of the American Medical Association 254, 3435-8.
117. Griffin, P. J., Colbert, J. W., Williamson, E. P. M., Fiddian, A. P., Hickmott, E., Sells, R. A. et al. (1985). Oral aciclovir prophylaxis of herpes infections in renal transplant recipients. Transplantation Proceedings 17, 84-5.
118. Selby, P. J., Powles, R. L., Easton, D., Perren, T. J., Stolle, K., Jameson, B. et al. (1989). The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. British Journal of Cancer 59, 434-8.
119. Wacker, P., Hartmann, O., Benhamou, E., Salloum, E. & Lemerle, J. (1989). Varicella-zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplantation 4, 191-4.
120. Schuchter, L. M., Wingard, J. R., Piantadosi, S., Burns, W. H., Santos, G. W. & Saral, R. (1989). Herpes zoster infection after autologous bone marrow transplantation. Blood 74, 1424-7.
121. Locksley, R. M., Flournoy, N., Sullivan, K. M. & Meyers, J. D. (1985). Infection with varicella-zoster virus after marrow transplantation. Journal of Infectious Diseases 152, 1172-81.
122. Hilt, D. C., Buchholz, D., Krumholz, A., Weiss, H. & Wolinsky, J. S. (1983). Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Annals of Neurology 14, 543-53.
123. Wilson, A., Sharp, M., Koropchak, C. M., Ting, S. F. & Arvin, A. M. (1992). Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. Journal of Infectious Diseases 165, 119-26.
124. Redman, R. L., Nader, S., Zerboni, L., Liu, C., Wong, R. M., Brown, B. W. et al. (1997). Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunised with inactivated varicella vaccine. Journal of Infectious Diseases 176, 578-85.
125. Feldman, S. & Lott, L. (1987). Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 80, 465-72.
126. Prober, C. G., Kirk, R. E. & Keeney, R. E. (1982). Acyclovir therapy for chickenpox in immunosuppressed children - A collaborative study. Journal of Pediatrics 101, 622-5.
127. Shepp, D. H., Dandliker, P. S. & Meyers, J. D. (1986). Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. New England Journal of Medicine 314, 208-12.
128. Balfour, H. H., Bean, B., Laskin, O. L., Ambinder, R. F., Meyers, J. D., Wade, J. C. et al. (1983). Acyclovir halts progression of herpes zoster in immunocompromised patients. New England Journal of Medicine 308, 1448-53.
129. Breton, G., Fillet, A. M., Katlama, C., Bricaire, F. & Caumes, E. (1998). Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients results of foscarnet therapy. Clinical Infectious Diseases 27, 1525-27.
130. Immunisation Against Infectious Diseases. (1996). HMSO, UK.
131. Morgan, E. R. & Smalley, L. A. (1983). Varicella in immunocompromised children: incidence of abdominal pain and organ involvement. American Journal of Diseases of Children 137, 883-5.
132. Feldhoff, C. M., Balfour, H. H., Jr, Simmons, R. L., Najarian, J. S. & Mauer, S. M. (1981 ). Varicella in children with renal transplants. Journal of Paediatrics 98, 25-31.
133. Giacchino, R., Marcellini, M. & Timitilli, A., Degli Innocenti, L., Losurdo, G., Palumbo, M. et al. (1995). Varicella vaccine in children requiring renal or hepatic transplantation. Transplantation 60, 1055-6.
134. Broyer, M., Tete, M. J., Guest, G., Gagnadoux, M. F. & Rouzioux, C. (1997). Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Paediatrics 99, 35-9.
135. Hanto, D. W., Frizzera, G., Gajl-Peczalska, K. J. & Simmons, R. L.
136. Knowles, D. M., Cesarman, E., Chadburn, A., Frizzera, G., Chen, J., Rose, E. A. et al. (1995). Correlative morphological and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 85, 552-65.
137. Shapiro, R. S., McClain, K., Frizzera, G., Gajl-Peczalska, K. J., Kersey, J. H., Blazar, B. R., Arthur, D. C. et al. (1988). Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71, 1231-43.
138. Zutter, M. M., Martin, P. J., Sale, G. E., Shulman, H. M., Fisher, L., Thomas, E. D. et al. (1988). Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Stood 72, 520-9.
139. Orazi, A., Hromas, R. A., Neiman, R. S., Greiner, T. C., Lee, C. H., Rubin, L. et al. (1997). Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. American Journal of Clinical Pathology 107, 419-29.
140. Hale, G., Cobbold, S. & Waldman, H. (1988). T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45, 753-9.
141. O'Reilly, R. J., Kernan, N. A. et al. (1988). Allogeneic transplants depleted of T cells by soybean lectin agglutination and E. rosette depletion. Bone Marrow Transplantations, 3 Suppl. 1, 3-6.
142. Crawford, D. H., Mulholland, N., Iliescu, V., Hawkins, R. & Powles, R. (1986). Epstein-Barr virus infection and immunity in bone marrow transplant recipients. Transplantation 42, 50-4.
143. Papadopoulos, E. B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M. H. et al. (1994). Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation. New England Journal of Medicine 330, 1185-91.
144. Rooney, C. M., Smith, C. A., Ng, C. Y., Loftin, S., Li, C., Krance, R. A. et al. (1995). Use of gene-modified virus-specific T. lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9-13.
145. Starzl, T. E., Nalesnik, M. A., Porter, K. A., Ho, M., Iwatsuki, S., Griffith, B. P. et al. (1984). Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet i, 583-7.
146. Shapiro, R. S., McClain, K., Frizzera, G., Gajl-Peczalska, K. J., Kersey, J. H., Blazar, B. R. et al. (1988). Epstein-Barr-virus-associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71, 1234-43.
147. Limaye, A. P., Huang, M. L., Atienza, E. E., Ferrenberg, J. M. & Corey, L. (1999). Detection of Epstein Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Journal of Clinical Microbiology 37, 1113-6.
148. Salahuddin, S. Z., Ablashi, D. V., Markham, P. D., Josephs, S. F., Sturzenegger, S., Kaplan, M. et al. (1986). Isolation of a new virus, (HBLV), in patients with lymphoproliferative disorders. Science 234, 596-601.
149. + T cells. Proceedings of the National Academy of Sciences, USA 87, 748-52.
150. Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M. et al. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865-9.
151. Drobyski, W. R., Knox, K. K., Majewski, D. & Carrigan, D. R. (1994). Brief report: fatal encephalitis due to variant B human herpesvirus-6 infection in bone marrow transplant recipient. New England Journal of Medicine 330, 1356-60.
152. Carrigan, D. R., Drobyski, W. R., Russler, S. K., Tapper, M. A., Knox, K. K. & Ash, R. C. (1991). Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 338, 147-9.
153. Drobyski, W. R., Dunne, W. M., Burd, E. M., Knox, K. K., Ash, R. C., Horowitz, M. M. et al. (1993). Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow suppressive role for HHV-6 in vivo. Journal of Infectious Diseases 167, 735-9.
154. Singh, N. & Carrigan, D. R. (1996). Human herpesvirus-6 in transplantation: an emerging pathogen. Annals of Internal Medicine 124, 1065-71.
155. Cone, R. W., Huang, M. L., Corey, L., Zeh, J., Ashley, R. & Bowden, R. (1999). Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. Journal of Infectious Diseases 179, 311-8.
156. Burns, W. H. & Sandford, G. R. (1990). Susceptibility of human herpesvirus 6 to antivirals in vitro. Journal of Infectious Diseases 162, 634-7.
157. DesJardin, J. A., Gibbons, L., Cho, E., Supran, S. E., Falagas, M. E., Werner, B. G. et al. (1998). Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. Journal of Infectious Diseases 178, 1783-6.
158. Osman, H. K., Peiris, J. S., Taylor, C. E., Warwicker, P., Jarrett, R. F. & Madeley, C. R. (1996). 'Cytomegalovirus Disease' in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? Journal of Medical Virology 48, 295-301.
159. Vivancos, P., Sarra, J., Palou, J., Valls, A., García, J. & Grañena, A. (1996). Kaposi's sarcoma after autologous bone marrow transplantation for multiple myeloma. Bone Marrow Transplantation 17, 669-71.
160. Erer, B., Angelucci, E., Muretto, P., Ripalti, M., Rapa, S., Gaziev, D. et al. (1997). Kaposi's sarcoma after allogeneic bone marrow transplantation. Bone Marrow Transplantation 19, 629-31.
161. Farge, D. (1993). Kaposi's sarcoma in organ transplant recipients: the Collaborative Transplantation Research Group of lle de France. European Journal of Medicine 2, 339-43.
162. al-Sulaiman, M. H. & al-Khader, A. A. (1994). Kaposi's sarcoma in renal transplant recipients. Transplant Science 4, 46-60.
163. Qunibi, W., Akhtar, M., Sheth, K., Ginn, H. E., Al-Furayh, O., DeVol, E. B. et al. (1988). Kaposi's sarcoma: the most common tumor after renal transplantation in Saudi Arabia. American Journal of Medicine 84, 225-32.
164. Shmueli, D., Shapira, Z., Yussim, A., Nakache, R., Ram, Z. & Shaharabani, E. (1989). The incidence of Kaposi sarcoma in renal transplant patients and its relation to immunosuppression. Transplantation Proceedings 21, 3209-10.
165. Penn, I. (1995). Sarcomas in organ allograft recipients. Transplantation 60, 1485-91.
166. Cathomas, G., Tamm, M., McGandy, C. E., Hin, P. H., Gudat, F., Thiel, G. et al. (1997). Transplantation-associated malignancies: restriction of human herpes virus 8 to Kaposi's sarcoma. Transplantation 64, 175-8.
167. Hudnall, S. D., Rady, P. L., Tyring, S. K. & Fish, J. C. (1998). Serologic and molecular evidence of human herpesvirus 8 activation in renal transplant recipients. Journal of Infectious Diseases 178, 1791-4.
168. Bedani, P. L., Risichella, I. S., Strumia, R., Cavazzini, L., Gilli, P., Calastrini, C. et al. (1999). Kaposi's sarcoma in renal transplant recipients: pathogenetic relation between the reduced density of Langerhans cells and cyclosporin-A therapy. Journal of Nephrology 12, 193-6.
169. Gomez, E., Aguado, S., Rodriguez, M. & Alvarez-Grande, J. (1998). Kaposi's sarcoma after renal transplantation - disappearance after reduction of immunosuppression and reappearance seven years later after start of mycophenolate mofetil treatment. Nephrology Dialysis Transplantation 13, 3279-80.